

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Quantitative Real Time PCR of Deoxycytidine Kinase mRNA by Light Cycler PCR; in Relation to Enzyme Activity

J. Sigmond^a; W. J. Loves^a; J. R. Kroep^a; G. J. Peters^a

^a Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

Online publication date: 27 October 2004

To cite this Article Sigmond, J. , Loves, W. J. , Kroep, J. R. and Peters, G. J.(2004) 'Quantitative Real Time PCR of Deoxycytidine Kinase mRNA by Light Cycler PCR; in Relation to Enzyme Activity', *Nucleosides, Nucleotides and Nucleic Acids*, 23: 8, 1347 – 1350

To link to this Article: DOI: 10.1081/NCN-200027611

URL: <http://dx.doi.org/10.1081/NCN-200027611>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Quantitative Real Time PCR of Deoxycytidine Kinase mRNA by Light Cyclers PCR; in Relation to Enzyme Activity

J. Sigmond,* W. J. Loves, J. R. Kroep, and G. J. Peters

Department of Medical Oncology, VU University Medical Center,
Amsterdam, The Netherlands

ABSTRACT

Deoxycytidine kinase (dCK) is essential for the phosphorylation of several deoxyribonucleosides and various analogues such as gemcitabine (2',2'-difluorodeoxycytidine). We developed and optimized a sensitive real time Light Cycler (LC) PCR assay for dCK with SYBR green detection. The enzymatic activity measured in the same human xenografts of dCK correlated excellently with dCK mRNA expression levels measured by the LC. This assay can be used for evaluation of dCK expression in tumors.

Key Words: Deoxycytidine kinase; Competitive template-RT-PCR; Light cyclers PCR.

INTRODUCTION

Deoxyribonucleoside analogues such as cytosine arabinoside (Ara-C) or gemcitabine (2',2'-difluorodeoxycytidine) are dependent on the enzyme deoxycytidine kinase (dCK) for its activity.^[1] These drugs are widely used chemotherapeutic agents in leukemia and solid

*Correspondence: J. Sigmond, Department of Medical Oncology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.

tumors, respectively. For evaluation of dCK mRNA expression, we earlier developed a conventional Competitive Template Reverse Transcriptase Polymerase Chain Reaction assay (CT-RT-PCR).^[2] However, real time PCR enables more rapid and sensitive detection of mRNA expression using either SYBR Green or fluorescent probes using a Light Cycler (LC). We developed and optimized a sensitive real time PCR assay for dCK with SYBR green detection.

MATERIALS AND METHODS

Tissues were immediately frozen in liquid nitrogen. RNA was isolated from pulverized tissues using RNeasy (Qiagen). RNA was reverse-transcribed to cDNA using random hexamers as described previously.^[2] Cell pellets were suspended in an aliquot of 200 μ l of RNeasy per 10⁶ cells. Twenty micrograms of the isolated RNA was used for reverse transcription into cDNA. Random hexamers were used as primers for Moloney murine leukemia virus reverse transcriptase (M-MLV-RT) at a concentration of 0.045 μ g/ μ l. After a brief incubation at 56°C to remove secondary structures, samples were quickly cooled down on ice and annealing of the hexamers also took place on ice. The extension of the primers was at 42°C using M-MLV-RT. The reaction was terminated by heating at 95°C for 5 min. cDNA samples were stored at -20°C until further use. The assay for dCK mRNA expression was optimized for the LC real-time PCR apparatus (Roche Diagnostics). Primers for dCK were based on those described for conventional PCR:^[2] forward primer: 5'-GAAGGGAACATCGCTGCAGG; reverse primer: 5'-TGGCCAAATTGGTTATTCATCC. The primers for β -Actin were similar to those described for conventional PCR: forward: 5'-GAT TCC TAT GTG GGC GAC GAG and reverse: 5'-CCA TCT CTT GCT CGA AGT CC. A Master SYBR Green I working solution was prepared by mixing 60 μ l of LightCycler-FastStart Reaction Mix SYBR Green I with 4 μ l of LC-FastStart Enzyme (Roche Laboratories). Two volumes of this working solution were mixed with 16 volumes of varying concentrations of MgCl₂, dCK or β -Actin primers and H₂O. Thereafter, 18 μ l of this solution was pipetted into a LC capillary. The reaction was started after the addition of 2 μ l cDNA of varying dilutions from tumor cells. For dCK, the final optimal concentration of MgCl₂ was 3 mM and that of the primer 0.7 μ M. For β -Actin these concentrations were 5 mM and 0.9 μ M. The dCK PCR program consisted of an initial denaturation step at 95°C for 10 minutes, followed by 45 cycles of 10 sec at 95°C, 5 sec at 60°C and 17 sec at 72°C. For β -Actin the PCR program was similar to that of dCK, except for the elongation time of 22 sec instead of 17 sec. Melting curves were produced to verify the purity of the products. In order to confirm the purity of the PCR products they were also analyzed on an agarose gel. Standard curves were produced to measure the expression of dCK which was quantified relative to β -Actin.

RESULTS AND DISCUSSION

Optimal conditions for LC real time PCR are different from those for conventional PCR. We optimized the PCR procedure by using various MgCl₂ and primer concentrations, as well as various annealing temperatures for both dCK and β -Actin.




Figure 1. Representative analysis of dCK gene expression using the LC Real Time PCR. Each line represents a different dilution of cDNA prepared from the leukemic CEM cell line (from left to right: 3, 10, 30, 100, 300, 1000, 3000, 10000 times diluted). Cp is calculated from the intercept of the lines with the X-axis, according to Roche software.

Crossing-points (Cp) defined by the program and the evaluation of melting curves were used for this optimization. Conditions as described in the previous section appeared to be optimal and we found linearity over a 10000-fold range (Fig. 1).

In addition, we observed a good correlation (Pearson: $r = 0.972$; $p = 0.003$) between LC-PCR and enzyme activity. Earlier reports describe real time PCR of dCK with Taqman using fluorescent probes specifically designed for the target.^[3,4] However in this study, for the first time a quantitative real time PCR has been developed for dCK that uses SYBR Green fluorescent dye to detect amplification of specific PCR products. This technique provides great flexibility because no target-specific probes are required and yet specific products can be distinguished from non-specific products by studying melting peak profiles. Because Kroep et al showed that pretreatment dCK levels predict *in vivo* gemcitabine sensitivity^[5] the SYBR Green LC-PCR for dCK is applicable in the clinic to predict chemotherapeutic agent sensitivity.

REFERENCES

1. Bergman, A.M.; Pinedo, H.M.; Peters, G.J. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). *Drug Resist. Updat.* **2002**, *5*, 19–33.
2. Van der Wilt, C.L.; Kroep, J.R.; Loves, W.J.; Rots, M.G.; Van Groeningen, C.J.; Kaspers, G.J.; Peters, G.J. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. *Eur. J. Cancer* **2003**, *39*, 691–697.
3. Galmarini, C.M.; Clarke, M.L.; Falette, N.; Puisieux, A.; Mackey, J.R.; Dumontet, C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. *Int. J. Cancer* **2002**, *97*, 239–245.

4. Mansson, E.; Liliemark, E.; Soderhall, S.; Gustafsson, G.; Eriksson, S.; Albertioni, F. Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia. *Leukemia* **2002**, *16*, 386–392.
5. Kroep, J.R.; Loves, W.J.; van der Wilt, C.L.; Alvarez, E.; Talianidis, I.; Boven, E.; Braakhuis, B.J.M.; van Groeningen, C.J.; Pinedo, H.M.; Peters, G.J. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. *Mol. Cancer Ther.* **2002**, *1*, 371–376.